

DAFTAR PUSTAKA

1. WHO. Cardiovascular diseases (CVDs) [Internet]. 2021 [cited 2021 Nov 25]. Available from: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
2. White CJ. Carotid Artery Stenting. *J Am Coll Cardiol* [Internet]. 2015;64(7):722–31. Available from: <http://dx.doi.org/10.1016/j.jacc.2014.04.069>
3. Witha NF. Pengaruh Ekstrak Etanol Kulit Buah Kering Asam Kandis (*Garcinia Cowa Roxb*) Terhadap Kadar Kolesterol Total Mencit Putih Jantan. Andalas University; 2006.
4. Li B, Shen YH, He YR, Zhang WD. Chemical Constituents And Biological Activities of Pinus Species. *Chem Biodivers*. 2013;10(12):2133–60.
5. Wahyuni FS, Hui LS, Stanslas J, Lajis NHJ, Dachriyanus. In Vivo Study Of Tetraprenyltoluquinone, An Anticancer Compounds From *Garcinia Cowa Roxb*. *J Young Pharm*. 2017;9(2):296–8.
6. Dachriyanus, Sartika L, Kesuma M MM. The Effect Of Rubraxanthone On Total Cholesterol, Triglyceride, HDL and LDL In The Blood White Male Mice. *J Sci Pharm Technol*. 2006;11:12–5.
7. Mahabusarakam W., Proudfoot J., Taylor W. C. Inhibition Of Lipoprotein Oxidation by Prenylated Xanthenes Derived From Mangostin. 2000;33:643–659.
8. Susanti M. Pengujian Profil Farmakokinetika Rubrasanton Yang Diisolasi Dari Kulit Batang Asam Kandis *Garcinia cowa Roxb* Setelah Pemberian Secara Oral Pada Mencit. andalas university; 2019.
9. Syamsudin, Faizatun, and Rahayu L. HPLC Analysis and Pharmacokinetic Study of Mangostin After Orally Administration in Rats. *Int J Pharm Biol Sci*. 2010;1(1):1–7.
10. Ramaiya A, Li G, M. Petiwala S, J. Johnson J. Single Dose Oral Pharmacokinetic Profile of α -Mangostin in Mice. *Curr Drug Targets*. 2012;13(14):1698–704.
11. Li L, Brunner I, Han AR, Hamburger M, Kinghorn AD, Frye R, et al. Pharmacokinetics of A-Mangostin in Rats After Intravenous and Oral Application. *Mol Nutr Food Res*. 2011;55(SUPPL. 1):67–74.
12. G E. A Handbook of Bioanalysis and Drug metabolism. United State of America: CRC Press; 2004.
13. Y H. Validasi Metode Analisis Rebamipid Dalam Plasma Secara Kromatografi Cair Kinerja Tinggi-Ultraviolet. 2009;1(3):156–67.
14. Harahap Y. Sample Preparation, Bioavailability and Bioequivalency. Jakarta: Jakarta; 2010.
15. Shargel L, Pong S wu YA. Biofarmasetika & Farmakokinetika Terapan.

Surabaya: Airlangga University Press; 2012.

16. Alen Y, Safitri N, Dachriyanus, Ali AM, Ladjis NH SM V. Rubraxhantone dari *Garcinia forbesii* KING. dan Bioaktivitasnya. 2008;1(2):192–201.
17. Alkadi KAA, Adam A, Taha M, Hasan MH SS. Prenylated Xanthone And Rubraxanthone With Antiplatelet Aggregation Activity In Human Whole Blood Isolated from *Garcinia griffithii*. 2013;29(4):1291–5.
18. Pattalung P, Wiriyachitra P, Ongsakul M. the Antimicrobial Activities of Rubraxanthone Isolated From *Garcinia Parvifolia* (Miq.) Miq. Vol. 14, Journal of the Science Society of Thailand. 1988. p. 67–71.
19. Dachriyanus, Asjar NS, Susanti M. Determination of Rubraxanthone in The Latex of Asam Kandis (*Garcinia cowa* Roxb) by Reverse Phase High Performance Liquid Chromatography. Pharmacogn J. 2017;9(2):288–91.
20. Wahyuni FS, Byrne LT, Dachriyanus, Dianita R, Jubahar J, Lajis NH et al. A New Ring-Reduced Tetraprenyltoluquinone And A Prenylated Xanthone from *Garcinia cowa*. 2004;57(3):223–6.
21. Ee GCL, Daud S, Izzaddin SA RM. *Garcinia mangostana*: A Source Of Potential Anti-Cancer Lead Compounds Against CEM-SS Cell Line. J Asian Nat Prod Res. 2008;10(5):475–9.
22. Jantan I, Pizar MM, Idris MS, Taher M, Ali RM. In Vitro Inhibitory Effect of Rubraxanthone Isolated from *Garcinia parvifolia* on Platelet-Activating Factor Receptor Binding. Planta Med. 2002;68(12):1133–4.
23. Wahyuni FS, Ali DAI, Lajis NH, Dachriyanus. Anti-Inflammatory Activity of Isolated Compounds From The Stem Bark of *Garcinia cowa* Roxb. Pharmacogn J. 2017;9(1):55–7.
24. Lee H CH. 1,3,6-trihydroxy-7-methoxy-8-(3,7-dimethyl-2,6-octadienyl) Xanthone from *Garcinia cowa*. Phytochemistry. 1997;16(2):20038–40.
25. Wahyuni FS, Shaari K, Stanslas J, Lajis NH, Dachriyanus. Cytotoxic Xanthones from the Stem Bark of *Garcinia cowa* Roxb. J Chem Pharm Res. 2015;7(1):227-236 (1).
26. Gopalakrishnan G, Banumathi B, Suresh G. Evaluation Of The Antifungal Activity Of Natural Xanthones from *Garcinia mangostana* and Their Synthetic Derivatives. J Nat Prod. 1997;60(5):519–24.
27. Syamsudin, Tjokrosonto S., Supargiyono, Wahyuono S. and M. In Vitro and In Vivo Antiplasmodial Activities of Active. 2009;
28. Sampath PD, Vijayaragavan K. Ameliorative Prospective Of Alpha-Mangostin, A Xanthone Derivative from *Garcinia mangostana* Against B-Adrenergic Cathecolamine-Induced Myocardial Toxicity And Anomalous Cardiac TNF-A And COX-2 Expressions In Rats. Exp Toxicol Pathol. 2008;60(4–5):357–64.
29. Sakagami Y, Iinuma M, Piyasena KGNP, Dharmaratne HRW. Antibacterial Activity of α -mangostin Against Vancomycin Resistant Enterococci (VRE) and Synergism with Antibiotics. Phytomedicine. 2005;12(3):203–8.

30. Chen LG, Yang LL WC. Anti-Inflammatory Activity Of Mangostins from *Garcinia mangostana*. *Food Chem Toxicol*. 2008;46(2):688–93.
31. Lin J, Gao Y, Li H, Zhang L LX. DNA Protective Effect Of Mangosteen Xanthenes: An In Vitro Study On Possible Mechanisms. *Adv Pharm Bull*. 2014;4(2):147–53.
32. Wahyuni FS, Ikhwan R Sudji RA. Evaluasi Sitotoksik Alfa Mangostin Pada Kultur Sel Leukosit Manusia Secara In Vitro dan Uji Aktivitas Antioksidan. *J Sains Farm dan Klin*. 2018;3(5):201–6.
33. Williams, P.; Ongsakul, M.; Proudfoot, J.; Croft K., Beilin L. Mangostin Inhibits The Oxidative Modification Of Human Low Density Lipoprotein. *Free Radic Res*. 1995;23:175–18.
34. Steen Honoré Hansen SP-B. *Bioanalysis of Pharmaceuticals Sample Preparation, Separation Techniques, and Mass Spectrometry*. Ltd JW& S, editor. West Sussex; 2015.
35. Wenkui Li, Wenying Jian YF. *Sample Preparation in LC-MS Bioanalysis*. new jersey; 2019.
36. Sherwood L. *Fisiologi Manusia: dari Sel Ke Sistem Edisi Kedua*. Jakarta: Penerbit Buku Kedokteran ECG; 1996.
37. Poedjaji A. *Dasar-Dasar Biokimia*. Jakarta: UI Press; 1994.
38. Rosenbaum S. *Basic Pharmacokinetics and Pharmacodynamics*. USA: John Wiley and Sons; 2011.
39. Kelly M. *Drug Analysis in Biological Fluids*. Dalam: *Chemical Analysis in Complex Matrices*. New York: Ellis Horwood; 1992.
40. D R. *Metode Kromatografi : Prinsip Dasar, Praktikum dan Pendekatan Pembelajaran Kromatografi*. Yogyakarta: Deepublish; 2017.
41. J S. *Encyclopedia of Pharmaceutical Technology*. 2007;1.
42. Gandjar, I.G.,& Rohman A. *Kimia Farmasi Analisis*. Yogyakarta: Pustaka Belajar; 2007.
43. Johnson EL dan RS. *Dasar Kromatografi Cair*. Terj. Kosasih padmawinata. Bandung: ITB Press; 1991.
44. Effendy. *Kromatografi Cair Kinerja Tinggi Dalam Bidang Farmasi*. Sumatera Utara: USU; 2004.
45. Susanti M D. *Kromatografi Cair Kinerja Tinggi*. Padang: Andalas University Press; 2014.
46. Leba MAU. *Buku Ajar Ekstraksi dan Real Kromatografi*. Yogyakarta: Deepublish; 2017.
47. Moein MM, El Beqqali A, Abdel-Rehim M. *Bioanalytical Method Development And Validation: Critical Concepts And Strategies*. *J Chromatogr B Anal Technol Biomed Life Sci* [Internet]. 2017;1043:3–11. Available from: <http://dx.doi.org/10.1016/j.jchromb.2016.09.028>
48. FDA. *Bioanalytical Method Validation Guidance for Industry*. 2018;

49. EMEA. Guideline On Bioanalytical Method Validation Guideline On Bioanalytical Method Validation Table Of Contents. 2012;1–23.
50. Nováková L, Solichová D, Solich P. Advantages Of Ultra Performance Liquid Chromatography Over High-Performance Liquid Chromatography: Comparison Of Different Analytical Approaches During Analysis Of Diclofenac Gel. *J Sep Sci*. 2006;29(16):2433–43.
51. Hansen SH BS. *Bioanalysis of Pharmaceuticals Sample Preparation, Separation Techniques, and Mass Spectrometry*. Chicester: West Sussex: John Wiley & Sons Ltd; 2015.
52. Polson C, Sarkar P, Incledon B, Raguvaran V, Grant R. Optimization Of Protein Precipitation Based Upon Effectiveness Of Protein Removal And Ionization Effect In Liquid Chromatography-Tandem Mass Spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci*. 2003;785(2):263–75.

